Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Lumen Technologies Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.95 (market cap $4.71B), while Lumen Technologies Inc trades at $5.56 (market cap $6.10B). The key difference: Lumen Technologies Inc is the larger of the two by market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Lumen Technologies Inc for 40 Days on average.
| DFTX | LUMN | |
|---|---|---|
Market Cap | $4.71B | $6.10B |
Volume | 1,966,636 | 10,497,830 |
Sector | Health | Media |
52-Week High | $48.45 | $11.83 |
52-Week Low | $10.68 | $5.53 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $3.67B | $17.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LUMN trades at $5.91, up 0.08% today, but technical indicators are bearish with RSI-6 at 78.82 suggesting overbought conditions. The company reported a net loss of $1.74 billion in 2025, with revenue declining to $12.40 billion, though it beat EPS estimates in two of the last three quarters. Recent news includes a planned stock exchange transfer to Nasdaq and the launch of Intelligent Internet to target AI-driven enterprise networking growth.
The outlook remains challenging due to persistent losses and high debt, but strategic shifts toward AI and digital services offer potential upside. Risks include steep legacy revenue declines and negative profitability metrics. Analyst consensus is cautious, with a 'Reduce' rating prevalent, reflecting skepticism about near-term turnaround prospects despite institutional buying interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
